Registration for a live webinar on 'Precision medicine treatment for anticancer drug resistance' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Overview - RNA interference as an antiviral tool
- RNA interference pathway
- RNA interference methods
- Antisense vs. RNAi
- Inhibition of HIV-1 by RNAi
- Virus inhibition by RNAi - RNA viruses
- Virus inhibition by RNAi - DNA viruses
- Coxsackievirus B3 (CVB-3)
- Picornavirus replication
- Dilatated cardiomyopathy (DCM)
- Overview - design of efficient siRNAs
- siRNAs targeting the Coxsackievirus 5' UTR
- siRNAs against 5' UTR of CVB-3 have no effect
- Screening for efficient siRNAs against TRPV1
- What makes an efficient siRNA?
- Efficient siRNA - strand bias or target structure?
- Accessible nucleotides at 3' or 5' end of target site
- Activation of seemingly inactive siRNA
- Folding of artificial siRNA targets
- siRNA silencing and local stability - correlation
- Model for determinants of siRNA efficiency
- Overview - inhibition of coxsackievirus replication
- Targeting the viral RdRP
- Coxsackievirus replication in cell culture
- Cell viability assay with siRdRP 1-4
- Inhibition of virus replication by siRNA
- Inhibition of Coxsackievirus B3 by siRNA
- CVB-3 inhibition in vivo
- Overview - strand selectivity of virus silencing
- Replication cycle of picornaviruses
- Selective strand silencing
- Strand-selectivity of siRdRP
- Design of siRNAs targeting the RdRP (-)-strand
- Strand-specificity of silencing
- Strand specific siRNAs
- Strand-inactivation by incorporation of LNA
- siRNA vs. siLNA
- Overview - SiDEx
- Silencing of RdRP by shRNA expression plasmid
- Long-term silencing generates escape mutants
- Silencing of mutated RdRP
- SiRNA double expression vector (SiDEx)
- SiDEx silences two target sites
- SiDEx silences wt and mutated RdRP
- SiDEx - silencing of mutated RdRP
- Silencing of mutated target site 4
- Overview - silencing of CAR
- Coxsackievirus-adenovirus-receptor (CAR)
- Screening for efficient siRNAs targeting CAR
- Efficiency of CAR-siRNAs
- Duration of silencing
- Inhibition of virus propagation by CAR-siRNA
- SiDEx vector against two target sites of CVB-3
- Summary
- Acknowledgement
Topics Covered
- Coxsackievirus B3
- Design of efficient antiviral siRNAs
- Plaque reduction assays
- Virus escape
- siRNA double expression vectors (SiDEx)
- Strand selectivity of virus silencing
- Silencing of the host receptor (Coxsackievirus-adenovirus receptor)
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Kurreck, J. (2007, October 1). RNAi and viral heart infections [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 22, 2024, from https://doi.org/10.69645/FJIU3524.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Jens Kurreck has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.